The Administration for Strategic Preparedness and Response (ASPR) has announced the first award using HHS’ delegated Defense Production Act (DPA) Title III authorities. Under the agreement, ASPR’s Office of Industrial Base Management and Supply Chain (IBMSC) will provide $12 million to Meissner to build a 70,000-square-foot facility in the southeast United States for X-ray sterilization capacity to safely manufacture medical devices and pharmaceutical products in the United States and reduce reliance on foreign suppliers.
The ASPR IBMSC DPA Title III program targets investments that create, maintain, protect, expand, or restore domestic industrial base capabilities that are critical to preparing for, responding to, and recovering from both current and future public health emergencies.
The award was made through ASPR’s Biomedical Advanced Research and Development Authority (BARDA) Biopharmaceutical Manufacturing Preparedness (BioMaP) Consortium, managed by Advanced Technologies International.